Australia Ranked As Second Most Expensive Country For Clinical Trials; Medicines Australia Calls For Reform
This article was originally published in PharmAsia News
Executive Summary
A strong currency and cumbersome rules have contributed to Australia becoming the second-most expensive country for clinical trials, and neighboring countries are taking advantage.
You may also be interested in...
Australia's New R&D Tax Credit Expected To Inject Funds Into Local Biotech Industry - And Multinational Subsidiaries?
MELBOURNE, Australia - Many in the Australian life sciences industry view the nation's new R&D Tax Credit, which became law in August 2011 with the passing of the Tax Laws Amendment (Research and Development) Bill 2010, as a marked improvement on the R&D Tax Concession it replaces
Australia Department Of Innovation Releases 10-Year Plan On Pharma Strategy
PERTH, Australia - Australia's Minister for Innovation, Industry, Science and Research, Senator Kim Carr, has released a sweeping report that outlines a 10-year plan for the country's pharmaceutical and biotech industry
Prima Shifts Focus To LAG-3 After Immutep Deal
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.